[ ZAI Lab raises $30M in Series C ]

ZAI Lab has raised  $30 million in Series C funding.

Founded in 2013, ZAI Lab  is engaged in the research, development and commercialization of omadacycline for the treatment of autoimmune and infectious diseases.

The start-up plans to use the latest proceeds to invest in its research and development, as well as support future partnering activities.

Funding  Series C
Founded  2013
Country  China
City  Shangai
Founder / CEO  Samantha DU
Deal Size  $30M
Investors  Rock Springs Capital
 Cormorant Asset Management
 Vivo Capital
 OrbiMed
Previous Investors  TF Capital
 Qiming Venture Partners
 Sequoia Capital
 Kleiner Perkins Caufield & Byers
 OrbiMed
 Advantech Capital